Immunoassay Analyzer Rapidly Assesses Cardiac Markers
|
By LabMedica International staff writers Posted on 16 Jul 2012 |

Image: the AQT90 FLEX immunoassay analyzer offers a comprehensive cardiac panel and markers for coagulation, infection, and pregnancy (Photo courtesy of Radiometer).
A fully automated immunoassay analyzer offers a comprehensive cardiac panel. The analyzer also offers markers for coagulation, infection, and pregnancy.
Called the AQT90 FLEX immunoassay analyzer, it utilizes a time-resolved fluorescence method to detect sandwich complexes formed between capture antibodies, europium chelate-labelled fluorescent tracer antibodies, and the antigen of interest.
The analyzer offers quality control and comprehensive system quality checks of every process to ensure that each test is performed error-free, providing accurate results at the point of care. It minimizes background fluorescence and detects small amounts of analyte.
The analyzer is a Radiometer (Crawley, United Kingdom) product. The companies IT systems provide complete remote control of decentrally placed analyzers that emulate the data control and flow of a central laboratory, with the potential to encompass multiple hospitals within a region.
Barnsley Hospital (Barnsley, United Kingdom) has recently installed Radiometer’s AQT90 FLEX analyzer in its emergency department, where it enables rapid assessment of patients presenting with chest pain. Dr James Griffiths, a consultant in emergency medicine at the hospital, described studies using Radiometer’s AQT90 FLEX. He stated that it provided "a closed system that is extremely easy to use; the sample tube is placed directly in the analyzer, eliminating the need for further handling of samples and reagents. Low risk patients undergo cardiac marker assessment on arrival and again at 90 minutes. If the test results and the accompanying electrocardiograms (ECGs) are normal, they can be discharged within four hours, avoiding the 12-hour wait associated with the traditional troponin test. It’s better for the patient, and the benefit to the hospital is that it reduces admissions and relieves pressure on acute care beds."
Related Links:
Radiometer
Barnsley Hospital
Called the AQT90 FLEX immunoassay analyzer, it utilizes a time-resolved fluorescence method to detect sandwich complexes formed between capture antibodies, europium chelate-labelled fluorescent tracer antibodies, and the antigen of interest.
The analyzer offers quality control and comprehensive system quality checks of every process to ensure that each test is performed error-free, providing accurate results at the point of care. It minimizes background fluorescence and detects small amounts of analyte.
The analyzer is a Radiometer (Crawley, United Kingdom) product. The companies IT systems provide complete remote control of decentrally placed analyzers that emulate the data control and flow of a central laboratory, with the potential to encompass multiple hospitals within a region.
Barnsley Hospital (Barnsley, United Kingdom) has recently installed Radiometer’s AQT90 FLEX analyzer in its emergency department, where it enables rapid assessment of patients presenting with chest pain. Dr James Griffiths, a consultant in emergency medicine at the hospital, described studies using Radiometer’s AQT90 FLEX. He stated that it provided "a closed system that is extremely easy to use; the sample tube is placed directly in the analyzer, eliminating the need for further handling of samples and reagents. Low risk patients undergo cardiac marker assessment on arrival and again at 90 minutes. If the test results and the accompanying electrocardiograms (ECGs) are normal, they can be discharged within four hours, avoiding the 12-hour wait associated with the traditional troponin test. It’s better for the patient, and the benefit to the hospital is that it reduces admissions and relieves pressure on acute care beds."
Related Links:
Radiometer
Barnsley Hospital
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
Human papillomavirus (HPV)-associated head and neck cancers are frequently treated with surgery, but some patients experience recurrence due to residual microscopic disease. Postoperative decisions about... Read more
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








